Why Is VSee Health Stock Down 55% Today?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Listing Qualifications Department has denied VSee Health's request for continued listing. While the company intends to appeal this decision, it expects shares to be delisted from the exchange when markets open on Thursday. When this happens, the company intends for its shares to be listed on OTC Markets (OTCM).
VSee Health stock was down 53.79% in pre-market trading on Monday, following a 3.65% dip on Friday. This extended the company's 2.94% drop year-to-date and 38.6% fall over the past 12 months.
Is VSee Health Stock a Buy, Sell, or Hold?
Turning to Wall Street, analyst coverage of VSee Health is lacking. Luckily, TipRanks' AI analyst Spark has it covered. Spark rates VSEE stock a Neutral (46) with no price target. It cites 'strong revenue growth and recent strategic contracts' as reasons for this stance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic fibrosis bronchiectasis (NCFB) approved by the US Food and Drug Administration (FDA). Brinsupri has been approved to treat adults and children aged 12 years and over with NCFB. The illness is a form of bronchiectasis not caused by cystic fibrosis, instead with airway damage arising from lung infections or inflammatory disorders, among others. Currently, bronchiectasis is treated through airway clearance procedures, antibiotic treatments, and exercise. However, until now, there has been no therapy specifically approved for the condition. Brinsupri, which is orally taken, is available in 10mg and 25mg tablets. GlobalData pharma analyst Vinie Varkey says: 'Brinsupri represents the first on-label non-antibiotic, anti-inflammatory treatment option that offers a more targeted action and possibly shift away from use of antibiotics in this disease space.' Shares in Nasdaq-listed Insmed closed 7.46% up at market close on 12 August and are currently trading around four times higher compared to a year ago, buoyed by the unveilings of positive clinical data. Brinsupri's approval was based on results from the Phase III ASPEN (NCT04594369) and Phase II WILLOW (NCT03218917) studies. ASPEN, which enrolled more than 1,700 NCFB patients, demonstrated a significant reduction in the annual rate of exacerbations for patients taking the medication. Exacerbations, also known as flare-ups, are endpoints often used in respiratory disease trials to measure therapy efficacy. Patients who received a 10mg dose of Brinsupri had a 21% reduction compared to those on placebo, while those who received a 25mg dose exhibited a 19% reduction. Varkey adds: 'As the first-to-market DPP-1 inhibitor in the respiratory field, Brinsupri is likely to become the standard of care in NCFB treatment. Key opinion leaders interviewed by GlobalData were excited by Brinsupri's ability to reduce exacerbations and slow the rate of lung function decline.' Insmed confirmed that applications for its drug have also been sent to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), with commercial launches anticipated in 2026. Brinsupri is already available in the US by prescription through a comprehensive speciality pharmacy network. The future for Brinsupri is looking bright in its untreaded indication. GlobalData reckons Insemed has a blockbuster on its hands, forecasting sales of $1.7bn by 2033. In an investor presentation, Insmed stated the drug could generate $5bn in peak sales. Around 500,000 people in the US are estimated to have NCFB, according to Insmed. GlobalData forecasts the bronchiectasis market to be worth $3.7bn in 2033 across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China). GlobalData is the parent company of Pharmaceutical Technology. Brinsupri joins the market alongside Insmed's only other commercial therapy, Arikayce (amikacin), approved in 2018 to treat Mycobacterium avium complex (MAC) lung disease. Varkey adds: 'For Insmed itself, Brinsupri's approval will be one that is instrumental in catapulting the company's profile as a key player within the respiratory space.' Her comments highlight an opportunity for DPP-1 inhibitors to expand into other respiratory indications, highlighting further growth avenues for biopharmas. "Insmed wins FDA approval for future blockbuster Brinsupri" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
Coinbase says just 5% in Bitcoin could supercharge your portfolio
Coinbase says just 5% in Bitcoin could supercharge your portfolio originally appeared on TheStreet. Coinbase (Nasdaq: COIN) thinks allocating only 5% of your portfolio to Bitcoin could do wonders. Coinbase Asset Management published a report on Aug. 12 in which it recommended five investing strategies to diversify into cryptocurrency. The simplest way forward is adding Bitcoin to a portfolio, Coinbase said, and recommended a 5% allocation to Bitcoin, as it greatly enhances returns and capitalizes on its 73% compound annual growth rate (CAGR) from January 2017 to June 2025. The king coin has generated a return of 14.28% during the same period. The report argued that a 5% allocation to Bitcoin instead of bonds outperformed the standard 60/40 equity-bond benchmark from 2018 onwards. Coinbase also recommended allocating 10% of a portfolio to Bitcoin and gold. Bitcoin is called the "digital gold," which, following the bullion's footsteps, has become a store of value. With gold's market cap at $20 trillion and Bitcoin's market cap at $2 trillion, the assets are among the most valued in the world. Coinbase created a store of value index composed of Bitcoin and gold in which the former's weight increases as its volatility decreases. Data suggests that the index outperformed the 60/40 equity-bond benchmark from 2020 onwards. MAG7 Crypto Basket: BlackRock, Coinbase, Circle, MicroStrategy Coinbase recommended another way for investors to gain exposure to cryptocurrency. It created a "MAG7 Crypto Basket" composed of equally weighted stocks of companies that are dedicated to crypto or exploring crypto technologies. The basket is composed of the following stocks: (i) the world's leading asset manager, BlackRock (NYSE: BLK), which issues crypto ETFs, (ii) Jack Dorsey's Bitcoin-centric fintech company, Block Inc. (NYSE: XYZ), (iii) Coinbase (Nasdaq: COIN) itself, which is the largest crypto exchange in the U.S., (iv) Circle (NYSE: CRCL), the crypto firm behind the second-largest stablecoin USDC, (v) the Bitcoin mining giant MARA Holdings (Nasdaq: MARA), (vi) the leading Bitcoin treasury firm, MicroStrategy (Nasdaq: MSTR), and (vii) the fintech firm PayPal (Nasdaq: PYPL), which also issues a stablecoin. While the risk-adjusted results of MAG7 outperform Bitcoin as a standalone asset, the drawdown is much more severe. "Bitcoin's fixed supply and decentralized nature position it as a hedge against higher inflation, enhancing portfolio resilience," the report said. Bitcoin was trading at $122,402.77 at the time of writing, up 2.2% in 24 hours. Disclaimer: The content above is intended for informational purposes only and should not be taken as financial advice. Do your own research before investing. Coinbase says just 5% in Bitcoin could supercharge your portfolio first appeared on TheStreet on Aug 13, 2025 This story was originally reported by TheStreet on Aug 13, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Estée Lauder, Vita Coco, Spectrum Brands, and Celsius Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets continued to rally as a surprisingly subdued inflation report fueled hopes for an imminent interest rate cut from the U.S. Federal Reserve. The July Consumer Price Index (CPI) report showed a year-over-year increase of 2.7%, which was slightly below market expectations. This tamer-than-expected inflation data was viewed by investors as a key signal that price pressures are easing. As a result, the market has strengthened its conviction that the U.S. Federal Reserve will implement an interest rate cut in September. The prospect of lower borrowing costs tends to boost corporate profitability and can stimulate economic activity, creating a more favorable environment for consumer-facing companies and fueling a broad-based market rally. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Personal Care company Estée Lauder (NYSE:EL) jumped 3.5%. Is now the time to buy Estée Lauder? Access our full analysis report here, it's free. Beverages, Alcohol, and Tobacco company Vita Coco (NASDAQ:COCO) jumped 3.1%. Is now the time to buy Vita Coco? Access our full analysis report here, it's free. Household Products company Spectrum Brands (NYSE:SPB) jumped 3.5%. Is now the time to buy Spectrum Brands? Access our full analysis report here, it's free. Beverages, Alcohol, and Tobacco company Celsius (NASDAQ:CELH) jumped 3.1%. Is now the time to buy Celsius? Access our full analysis report here, it's free. Zooming In On Estée Lauder (EL) Estée Lauder's shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Estée Lauder is up 28.4% since the beginning of the year, and at $95.01 per share, it is trading close to its 52-week high of $100.78 from September 2024. Investors who bought $1,000 worth of Estée Lauder's shares 5 years ago would now be looking at an investment worth $445.28. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
